HUE055942T2 - LPA génexpressziójának gátlására szolgáló készítmények és eljárások - Google Patents
LPA génexpressziójának gátlására szolgáló készítmények és eljárásokInfo
- Publication number
- HUE055942T2 HUE055942T2 HUE16852695A HUE16852695A HUE055942T2 HU E055942 T2 HUE055942 T2 HU E055942T2 HU E16852695 A HUE16852695 A HU E16852695A HU E16852695 A HUE16852695 A HU E16852695A HU E055942 T2 HUE055942 T2 HU E055942T2
- Authority
- HU
- Hungary
- Prior art keywords
- lpa
- compositions
- methods
- gene expression
- inhibiting gene
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235816P | 2015-10-01 | 2015-10-01 | |
US201662346304P | 2016-06-06 | 2016-06-06 | |
US201662383221P | 2016-09-02 | 2016-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE055942T2 true HUE055942T2 (hu) | 2022-01-28 |
Family
ID=58424351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16852695A HUE055942T2 (hu) | 2015-10-01 | 2016-09-30 | LPA génexpressziójának gátlására szolgáló készítmények és eljárások |
Country Status (37)
Country | Link |
---|---|
US (3) | US9932586B2 (hu) |
EP (2) | EP4029941A1 (hu) |
JP (4) | JP6991966B2 (hu) |
KR (1) | KR20180052703A (hu) |
CN (1) | CN108368506A (hu) |
AU (2) | AU2016331084B2 (hu) |
BR (1) | BR112018006489A2 (hu) |
CA (1) | CA3000397A1 (hu) |
CL (1) | CL2018000803A1 (hu) |
CO (1) | CO2018003678A2 (hu) |
CR (1) | CR20180231A (hu) |
CY (1) | CY1125263T1 (hu) |
DK (1) | DK3356529T3 (hu) |
EA (1) | EA038478B1 (hu) |
ES (1) | ES2896298T3 (hu) |
HK (1) | HK1259063A1 (hu) |
HR (1) | HRP20211410T1 (hu) |
HU (1) | HUE055942T2 (hu) |
IL (3) | IL300438A (hu) |
JO (2) | JOP20210043A1 (hu) |
LT (1) | LT3356529T (hu) |
MA (1) | MA43347B1 (hu) |
MX (2) | MX2018003833A (hu) |
MY (1) | MY195796A (hu) |
PE (1) | PE20181139A1 (hu) |
PH (1) | PH12018500713A1 (hu) |
PL (1) | PL3356529T3 (hu) |
PT (1) | PT3356529T (hu) |
RS (1) | RS62523B1 (hu) |
SG (1) | SG10202008530TA (hu) |
SI (1) | SI3356529T1 (hu) |
TN (1) | TN2018000094A1 (hu) |
TW (1) | TWI784934B (hu) |
UA (1) | UA121998C2 (hu) |
UY (1) | UY36926A (hu) |
WO (1) | WO2017059223A2 (hu) |
ZA (1) | ZA202106265B (hu) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718133B2 (en) | 2003-10-09 | 2010-05-18 | 3M Innovative Properties Company | Multilayer processing devices and methods |
CN113797348A (zh) * | 2016-03-07 | 2021-12-17 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
EP3506913A4 (en) * | 2016-09-02 | 2020-06-10 | Arrowhead Pharmaceuticals, Inc. | TARGETING LIGANDS |
RS63836B1 (sr) | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
CA3061752A1 (en) * | 2017-07-06 | 2019-01-10 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of alpha-enac and methods of use |
SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
CN117701562A (zh) * | 2017-09-14 | 2024-03-15 | 箭头药业股份有限公司 | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 |
US11492624B2 (en) * | 2017-10-17 | 2022-11-08 | Arrowheads Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 |
LT3710586T (lt) * | 2017-11-13 | 2023-02-27 | Silence Therapeutics Gmbh | Nukleorūgštis, skirta slopinti lpa raišką ląstelėje |
EP3483270A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
JP2022501040A (ja) * | 2018-09-19 | 2022-01-06 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 17β−HSD13型(HSD17B13)の発現を阻害するためのRNAi剤、その組成物、および使用方法 |
JP7245328B2 (ja) * | 2018-11-13 | 2023-03-23 | サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞におけるlpaの発現を抑制するための核酸 |
JP2023504744A (ja) | 2019-12-09 | 2023-02-06 | アムジエン・インコーポレーテツド | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
BR112023001957A2 (pt) * | 2020-08-05 | 2023-04-25 | Dicerna Pharmaceuticals Inc | Composições e métodos para inibir expressão de lpa |
WO2022079221A1 (en) * | 2020-10-16 | 2022-04-21 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
EP4240855A1 (en) | 2020-11-05 | 2023-09-13 | Amgen Inc. | Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs |
WO2022121959A1 (zh) * | 2020-12-09 | 2022-06-16 | 纳肽得有限公司 | siRNA分子及其在治疗冠状动脉疾病中的应用 |
WO2022136466A1 (en) | 2020-12-23 | 2022-06-30 | Argonaute RNA Limited | Treatment of cardiovascular disease |
CN117836307A (zh) | 2021-06-18 | 2024-04-05 | 弘景生物科技有限公司 | 功能化的n-乙酰基半乳糖胺核苷 |
US11692001B2 (en) | 2021-08-30 | 2023-07-04 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
WO2023041508A2 (en) | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
KR20240056619A (ko) * | 2021-09-18 | 2024-04-30 | 제노바 테라퓨틱스 컴퍼니 리미티드 | Lpa 억제제 및 이의 용도 |
CN114703184A (zh) * | 2022-03-11 | 2022-07-05 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
WO2024032681A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
JP4095895B2 (ja) * | 2000-12-01 | 2008-06-04 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Rna干渉を媒介する短鎖rna分子 |
US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
ATE471722T1 (de) | 2003-03-12 | 2010-07-15 | Univ Arizona State | Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen |
EP1742958B1 (en) | 2004-03-15 | 2017-05-17 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
CA3151965A1 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
MX2012009178A (es) | 2010-02-24 | 2012-11-30 | Arrowhead Res Corp | Composiciones para liberacion dirigida de arnsi. |
WO2011141703A1 (en) * | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
KR20130132475A (ko) | 2010-12-17 | 2013-12-04 | 애로우헤드 리서치 코오포레이션 | siRNA의 갈락토오스 클러스터-약동학적 조절제 표적 물질 |
CA2816041C (en) | 2010-12-29 | 2019-01-08 | Arrowhead Research Corporation | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
WO2013032829A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
KR20220045091A (ko) * | 2011-11-18 | 2022-04-12 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법 |
MX2014001965A (es) | 2012-04-18 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(acrilato) para suministro de acido nucleico in vivo. |
LT2855500T (lt) | 2012-05-24 | 2020-11-10 | Ionis Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti apolipoproteino (a) raiškos moduliacijai |
IL284593B2 (en) | 2013-05-01 | 2023-02-01 | Ionis Pharmaceuticals Inc | Compositions and methods for modulation of hbv and ttr expression |
US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
BR112017025698A2 (pt) | 2015-05-29 | 2018-08-14 | Arrowhead Pharmaceuticals Inc | composições e métodos para inibir a expressão do gene de hif2alfa |
BR112018000542B1 (pt) * | 2015-07-31 | 2023-01-24 | Alnylam Pharmaceuticals, Inc | Agente de ácido ribonucleico de fita dupla para inibição da expressão de transtiretina em uma célula, composição farmacêutica, uso dos anteriores, e método in vitro para inibição da expressão de transtiretina em uma célula |
CN113797348A (zh) | 2016-03-07 | 2021-12-17 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
-
2015
- 2015-10-01 JO JOP/2021/0043A patent/JOP20210043A1/ar unknown
-
2016
- 2016-09-28 JO JOP/2016/0211A patent/JOP20160211B1/ar active
- 2016-09-30 MY MYPI2018000440A patent/MY195796A/en unknown
- 2016-09-30 MX MX2018003833A patent/MX2018003833A/es unknown
- 2016-09-30 SI SI201631374T patent/SI3356529T1/sl unknown
- 2016-09-30 IL IL300438A patent/IL300438A/en unknown
- 2016-09-30 AU AU2016331084A patent/AU2016331084B2/en active Active
- 2016-09-30 KR KR1020187010095A patent/KR20180052703A/ko not_active Application Discontinuation
- 2016-09-30 EP EP21191363.7A patent/EP4029941A1/en active Pending
- 2016-09-30 UY UY0001036926A patent/UY36926A/es unknown
- 2016-09-30 EP EP16852695.2A patent/EP3356529B1/en active Active
- 2016-09-30 CN CN201680057095.8A patent/CN108368506A/zh active Pending
- 2016-09-30 DK DK16852695.2T patent/DK3356529T3/da active
- 2016-09-30 JP JP2018516738A patent/JP6991966B2/ja active Active
- 2016-09-30 CA CA3000397A patent/CA3000397A1/en active Pending
- 2016-09-30 US US15/281,309 patent/US9932586B2/en active Active
- 2016-09-30 PE PE2018000487A patent/PE20181139A1/es unknown
- 2016-09-30 UA UAA201804593A patent/UA121998C2/uk unknown
- 2016-09-30 ES ES16852695T patent/ES2896298T3/es active Active
- 2016-09-30 HR HRP20211410TT patent/HRP20211410T1/hr unknown
- 2016-09-30 LT LTEPPCT/US2016/054729T patent/LT3356529T/lt unknown
- 2016-09-30 EA EA201890864A patent/EA038478B1/ru unknown
- 2016-09-30 SG SG10202008530TA patent/SG10202008530TA/en unknown
- 2016-09-30 WO PCT/US2016/054729 patent/WO2017059223A2/en active Application Filing
- 2016-09-30 CR CR20180231A patent/CR20180231A/es unknown
- 2016-09-30 PT PT168526952T patent/PT3356529T/pt unknown
- 2016-09-30 HU HUE16852695A patent/HUE055942T2/hu unknown
- 2016-09-30 BR BR112018006489-0A patent/BR112018006489A2/pt active Search and Examination
- 2016-09-30 PL PL16852695T patent/PL3356529T3/pl unknown
- 2016-09-30 TN TNP/2018/000094A patent/TN2018000094A1/en unknown
- 2016-09-30 TW TW105131823A patent/TWI784934B/zh active
- 2016-09-30 RS RS20211351A patent/RS62523B1/sr unknown
-
2017
- 2017-04-06 MA MA43347A patent/MA43347B1/fr unknown
-
2018
- 2018-02-21 US US15/901,810 patent/US10662427B2/en active Active
- 2018-03-25 IL IL258333A patent/IL258333B/en unknown
- 2018-03-27 MX MX2022013010A patent/MX2022013010A/es unknown
- 2018-03-28 CL CL2018000803A patent/CL2018000803A1/es unknown
- 2018-03-28 PH PH12018500713A patent/PH12018500713A1/en unknown
- 2018-04-05 CO CONC2018/0003678A patent/CO2018003678A2/es unknown
-
2019
- 2019-01-29 HK HK19101563.4A patent/HK1259063A1/zh unknown
-
2020
- 2020-05-06 US US16/867,925 patent/US20200263179A1/en active Pending
-
2021
- 2021-03-12 JP JP2021039949A patent/JP7116212B2/ja active Active
- 2021-08-30 ZA ZA2021/06265A patent/ZA202106265B/en unknown
- 2021-11-08 CY CY20211100962T patent/CY1125263T1/el unknown
-
2022
- 2022-02-13 IL IL290566A patent/IL290566B2/en unknown
- 2022-06-15 JP JP2022096415A patent/JP7442574B2/ja active Active
- 2022-12-05 AU AU2022283623A patent/AU2022283623A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199857A patent/JP2024009262A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290566A (en) | Preparations and methods for preventing lipoprotein A gene expression | |
IL254518A0 (en) | Preparations and methods for suppressing the expression of the factor xii gene | |
IL268788A (en) | Preparations and methods for increased gene expression | |
IL273875A (en) | Methods and compounds for inhibiting expression of LDHA | |
HK1232163A1 (zh) | 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 | |
HK1252852A1 (zh) | 阻止HIF2α基因表達的組合物及方法 | |
HUE057327T2 (hu) | Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására | |
IL282747A (en) | Preparations and methods for inhibiting expression of the ALAS1 gene | |
PL3349743T3 (pl) | Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12 | |
ZA201803723B (en) | Compositions and methods for efficient targeting of transgenes | |
IL262459A (en) | Preparations and methods for increased gene expression of pklr |